RT Book, Section
A1 Mahmoud, Najjia N.
A2 Zinner, Michael J.
A2 Ashley, Stanley W.
A2 Hines, O. Joe
SR Print(0)
ID 1160043868
T1 Cancer of the Anus
T2 Maingot's Abdominal Operations, 13e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071843072
LK accesssurgery.mhmedical.com/content.aspx?aid=1160043868
RD 2024/04/19
AB Cancers  of  the  anus  are  rare  problems  with  diverse  histology.  While  squamous  cell  carcinoma  (SCC)  of  the  anal  canal  remains  by  far  the  most  common  of  these  neoplasms  and  the  main  focus  of  the  chapter,  the  anus  may  also  harbor  tumors  such  as  adenocarcinoma,  melanoma,  and  basal  cell  carcinoma.  The  treatment  of  anal  cancer  has  undergone  dramatic  changes  in  the  last  25  years.  Multimodality  treatment  consisting  of  radiation  and  chemotherapy  has  replaced  abdominoperineal  resection  or  wide  local  excision  as  the  mainstay  of  therapy.  Five-year  survival  rates  now  exceed  80%  and  radical  surgery  is  reserved  for  cancers  of  the  anal  canal  that  do  not  respond  to  chemoradiation  or  that  recur  locally.  Our  understanding  of  the  etiology  and  epidemiology  of  anal  SCC  and  its  precursor  lesions  has  also  profoundly  changed  in  the  past  few  decades  yielding  new  initiatives  in  both  therapy  and  prevention  that  may  further  alter  the  future  treatment  of  this  disease.  Anal  cancer  is  clearly  a  disease  that  benefits  from  multispecialty  intervention.  Because  of  this,  the  treatment  of  anal  cancer  serves  as  a  paradigm  for  the  multimodality  treatment  of  cancer.